Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, Bethesda, Maryland, USA.
Br J Haematol. 2022 Aug;198(4):740-744. doi: 10.1111/bjh.18311. Epub 2022 Jun 23.
We adjusted haematopoietic stem and progenitor cell (HSPC) apheresis collection from patients with sickle cell disease (SCD) by targeting deep buffy coat collection using medium or low collection preference (CP), and by increasing anticoagulant-citrate-dextrose-solution A dosage. In 43 HSPC collections from plerixafor-mobilized adult patients with SCD, we increased the collection efficiency to 35.79% using medium CP and 82.23% using low CP. Deep buffy coat collection increased red blood cell contamination of the HSPC product, the product haematocrit was 4.7% with medium CP and 6.4% with low CP. These adjustments were well-tolerated and allowed efficient HSPC collection from SCD patients.
我们通过使用中或低采集偏好（CP）以及增加抗凝剂-柠檬酸钠-葡萄糖溶液 A 剂量，调整镰状细胞病（SCD）患者的造血干细胞和祖细胞（HSPC）采集。在 43 例接受培利珠单抗动员的成年 SCD 患者的 HSPC 采集，我们使用中 CP 将采集效率提高到 35.79%，使用低 CP 将采集效率提高到 82.23%。深骨髓采集增加了 HSPC 产物的红细胞污染，中 CP 时产物的红细胞压积为 4.7%，低 CP 时产物的红细胞压积为 6.4%。这些调整是耐受良好的，并允许从 SCD 患者中高效采集 HSPC。
